Dianthus Therapeutics Net Worth
Dianthus Therapeutics Net Worth Breakdown | DNTH |
Dianthus Therapeutics Net Worth Analysis
Dianthus Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Dianthus Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Dianthus Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Dianthus Therapeutics' net worth analysis. One common approach is to calculate Dianthus Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Dianthus Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Dianthus Therapeutics' net worth. This approach calculates the present value of Dianthus Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Dianthus Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Dianthus Therapeutics' net worth. This involves comparing Dianthus Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Dianthus Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Dianthus Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Dianthus Therapeutics' net worth research are outlined below:
| Dianthus Therapeutics generated a negative expected return over the last 90 days | |
| Dianthus Therapeutics has high historical volatility and very poor performance | |
| Dianthus Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 6.24 M. Net Loss for the year was (84.97 M) with profit before overhead, payroll, taxes, and interest of 6.24 M. | |
| Dianthus Therapeutics generates negative cash flow from operations | |
| Dianthus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Were Not Very Worried About Dianthus Therapeutics Cash Burn Rate |
Dianthus Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Dianthus Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dianthus Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Dianthus Therapeutics Target Price Consensus
Dianthus target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Dianthus Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 12 | Strong Buy |
Most Dianthus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Dianthus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Dianthus Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationDianthus Therapeutics Target Price Projection
Dianthus Therapeutics' current and average target prices are 19.49 and 51.80, respectively. The current price of Dianthus Therapeutics is the price at which Dianthus Therapeutics is currently trading. On the other hand, Dianthus Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Dianthus Therapeutics Market Quote on 22nd of March 2025
Target Price
Analyst Consensus On Dianthus Therapeutics Target Price
Follow Dianthus Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 656.64 M.Market Cap |
|
Project Dianthus Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.23) | (0.24) | |
| Return On Capital Employed | (0.29) | (0.30) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.24) | (0.25) |
When accessing Dianthus Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Dianthus Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Dianthus Therapeutics' profitability and make more informed investment decisions.
Evaluate Dianthus Therapeutics' management efficiency
Dianthus Therapeutics has return on total asset (ROA) of (0.2301) % which means that it has lost $0.2301 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.326) %, meaning that it created substantial loss on money invested by shareholders. Dianthus Therapeutics' management efficiency ratios could be used to measure how well Dianthus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.24. The current Return On Capital Employed is estimated to decrease to -0.3. As of now, Dianthus Therapeutics' Total Current Assets are increasing as compared to previous years. The Dianthus Therapeutics' current Non Currrent Assets Other is estimated to increase to about 10.1 M, while Net Tangible Assets are projected to decrease to (41.9 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 10.30 | 9.78 | |
| Tangible Book Value Per Share | 10.30 | 9.78 | |
| Enterprise Value Over EBITDA | (7.12) | (7.47) | |
| Price Book Value Ratio | 2.12 | 2.01 | |
| Enterprise Value Multiple | (7.12) | (7.47) | |
| Price Fair Value | 2.12 | 2.01 | |
| Enterprise Value | 725.1 M | 761.3 M |
Understanding the operational decisions made by Dianthus Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 62.1824 | Revenue | Quarterly Revenue Growth 1.902 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dianthus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dianthus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dianthus Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dianthus Therapeutics Corporate Filings
| 19th of March 2025 Other Reports | ViewVerify | |
8K | 11th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 4th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Dianthus Therapeutics Earnings Estimation Breakdown
The calculation of Dianthus Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Dianthus Therapeutics is estimated to be -0.79 with the future projection ranging from a low of -0.79 to a high of -0.79. Please be aware that this consensus of annual earnings estimates for Dianthus Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.79 Lowest | Expected EPS | -0.79 Highest |
Dianthus Therapeutics Earnings Projection Consensus
Suppose the current estimates of Dianthus Therapeutics' value are higher than the current market price of the Dianthus Therapeutics stock. In this case, investors may conclude that Dianthus Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Dianthus Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 12 | 70.33% | -0.81 | -0.79 | -2.55 |
Dianthus Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Dianthus Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Dianthus Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Dianthus Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Dianthus Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Dianthus Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Dianthus Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Dianthus Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Dianthus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-03-19 | 2024-12-31 | -0.76 | -0.81 | -0.05 | 6 | ||
2024-11-07 | 2024-09-30 | -0.59 | -0.72 | -0.13 | 22 | ||
2024-08-08 | 2024-06-30 | -0.55 | -0.51 | 0.04 | 7 | ||
2024-05-09 | 2024-03-31 | -0.44 | -0.54 | -0.1 | 22 | ||
2024-03-21 | 2023-12-31 | -1.01 | -0.71 | 0.3 | 29 | ||
2023-11-09 | 2023-09-30 | -0.56 | -3.78 | -3.22 | 575 | ||
2023-09-18 | 2023-06-30 | -3.04 | -0.8663 | 2.1737 | 71 | ||
2023-05-11 | 2023-03-31 | -0.4 | -0.47 | -0.07 | 17 | ||
2023-03-07 | 2022-12-31 | -0.2762 | -0.3 | -0.0238 | 8 | ||
2022-11-03 | 2022-09-30 | -0.29 | -0.27 | 0.02 | 6 | ||
2022-08-04 | 2022-06-30 | -0.34 | -0.29 | 0.05 | 14 | ||
2022-05-16 | 2022-03-31 | -0.3181 | -0.39 | -0.0719 | 22 | ||
2022-03-08 | 2021-12-31 | -0.3169 | -0.33 | -0.0131 | 4 | ||
2021-11-04 | 2021-09-30 | -0.3285 | -0.3 | 0.0285 | 8 | ||
2021-08-05 | 2021-06-30 | -0.3725 | -0.32 | 0.0525 | 14 | ||
2021-05-06 | 2021-03-31 | -0.388 | -0.36 | 0.028 | 7 | ||
2021-03-03 | 2020-12-31 | -0.388 | -0.38 | 0.008 | 2 | ||
2020-11-05 | 2020-09-30 | -0.43 | -0.37 | 0.06 | 13 | ||
2020-08-06 | 2020-06-30 | -0.54 | -0.48 | 0.06 | 11 | ||
2020-05-07 | 2020-03-31 | -0.6 | -0.51 | 0.09 | 15 | ||
2020-03-03 | 2019-12-31 | -0.58 | -0.59 | -0.01 | 1 | ||
2019-11-13 | 2019-09-30 | -0.53 | -0.54 | -0.01 | 1 | ||
2019-08-08 | 2019-06-30 | -0.49 | -0.48 | 0.01 | 2 | ||
2019-05-09 | 2019-03-31 | -0.55 | -0.44 | 0.11 | 20 | ||
2019-03-19 | 2018-12-31 | -0.53 | -0.5 | 0.03 | 5 | ||
2018-11-08 | 2018-09-30 | -0.67 | -0.49 | 0.18 | 26 | ||
2018-08-09 | 2018-06-30 | -1.13 | -3.13 | -2.0 | 176 | ||
2018-05-30 | 2018-03-31 | 0 | -4.45 | -4.45 | 0 | ||
2018-02-03 | 2017-12-31 | 0 | -1.03 | -1.03 | 0 | ||
2017-05-04 | 2017-03-31 | 0 | -0.15 | -0.15 | 0 |
Dianthus Therapeutics Corporate Management
| Jennifer Ruff | VP Affairs | Profile | |
| Edward Carr | Chief Officer | Profile | |
| Kristina Maximenko | Chief Officer | Profile | |
| MD MBA | Chief Officer | Profile | |
| Adam Esq | General Counsel | Profile | |
| Judson Taylor | Senior Operations | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.55) | Revenue Per Share | Quarterly Revenue Growth 1.902 | Return On Assets | Return On Equity |
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dianthus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.